Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHVN Biohaven Pharmaceutical Holding Co Ltd.

Market Closed 06-05 16:00:00 EDT

10.80

-0.60

-5.26%

盘后10.72

-0.08-0.73%

19:43 EDT

High11.50	Low10.61	Vol2.04M
Open11.33	D1 Closing11.40	Amplitude7.81%
Mkt Cap1.62B	Tradable Cap1.34B	Total Shares150.42M
T/O22.20M	T/O Rate1.64%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BHVN","market":"US","secType":"STK","nameCN":"Biohaven Pharmaceutical Holding Co Ltd.","latestPrice":10.8,"timestamp":1780689600000,"preClose":11.4,"halted":0,"volume":2035989,"hourTrading":{"tag":"盘后","latestPrice":10.721,"preClose":10.8,"latestTime":"19:43 EDT","volume":33686,"amount":363687.8264,"timestamp":1780702990843,"change":-0.079,"changeRate":-0.007315,"amplitude":0.008259},"delay":0,"changeRate":-0.05263157894736839,"floatShares":124000000,"shares":150417084,"eps":-5.440705,"marketStatus":"Market Closed","change":-0.6,"latestTime":"06-05 16:00:00 EDT","open":11.33,"high":11.5,"low":10.61,"amount":22197518.699697,"amplitude":0.07807,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.440705,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NYSE","adjPreClose":11.4,"preHourTrading":{"tag":"盘前","latestPrice":11.25,"preClose":11.4,"latestTime":"09:18 EDT","volume":376,"amount":4194.440176,"timestamp":1780665527113,"change":-0.15,"changeRate":-0.013158,"amplitude":0.039474},"postHourTrading":{"tag":"盘后","latestPrice":10.721,"preClose":10.8,"latestTime":"19:43 EDT","volume":33686,"amount":363687.8264,"timestamp":1780702990843,"change":-0.079,"changeRate":-0.007315,"amplitude":0.008259},"volumeRatio":0.6182777494824524,"impliedVol":0.8365,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/BHVN","defaultTab":"news","newsList":[{"id":"2640189582","title":"Acting US FDA chief meets with rare disease groups to mend fences","url":"https://stock-news.laohu8.com/highlight/detail?id=2640189582","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640189582?lang=en_us&edition=fundamental","pubTime":"2026-06-04 03:10","pubTimestamp":1780513809,"startTime":"0","endTime":"0","summary":"Acting US FDA chief meets with rare disease groups to mend fencesRare disease groups seek regulatory clarity from FDA officialsDecisions by previous FDA chief disappointed such groupsActing commissioner seen as potential permanent nominee, sources sayBy Chris Prentice. 'SIGNIFICANT UNMET NEED'\"Meetings like this demonstrate FDA's continued commitment to address the real challenges facing the rare disease community and to advancing treatments in small-patient populations,\" Jeff Allen, CEO of Friends of Cancer Research, said in a statement.He said there were opportunities for novel trial designs and more efficient clinical trials, \"which could help accelerate new therapies to address areas of significant unmet need.\"A spokesperson for the Foundation for Angelman Syndrome Therapeutics, an advocacy group for patients with a rare neuro-genetic disorder, also confirmed attending the meeting. For diseases with small patient populations, regulatory clarity is needed to overcome challenges incl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL6N42B0TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","SRPT","BHVN","IE00B2B36J28.USD","LU1093756168.USD","IE00BJT1NW94.SGD","SRPU","IE00BFTCPJ56.SGD","BK4139","BK4585","IE00BJJMRZ35.SGD","IE0009355771.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640134908","title":"Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640134908","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640134908?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:20","pubTimestamp":1780478456,"startTime":"0","endTime":"0","summary":"Biohaven recently reported a series of pipeline advances, including first-in-human dosing of BHV-8100, its oral, brain-penetrant PKM2 modulator, alongside encouraging clinical data for autoimmune candidate BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy.\nThese updates showcase Biohaven’s push into metabolically targeted neurology and precision immunology, positioning its platforms around disease-causing antibodies and energy metabolism rather than symptom control alone.\nNext,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PRGS","LU2065732104.USD","LU1093756168.USD","LU1093756325.SGD","BHVN","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951533","title":"Biohaven Starts First Human Trial of BHV-8100 for Neurological, Retinal and Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951533","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951533?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:17","pubTimestamp":1780316220,"startTime":"0","endTime":"0","summary":"Biohaven  said Monday it has initiated first-in-human dosing of BHV-8100, an experimental oral, brain-penetrant PKM2 modulator being developed for neurological, retinal and inflammatory diseases.The Phase 1 study is evaluating the drug's safety, tolerability and pharmacokinetics in healthy volunteers, according to the company.Biohaven said early data showed BHV-8100 achieved projected therapeutic exposure levels, supported once-daily dosing and was generally well tolerated, with most adverse events reported as mild and spontaneously resolving.The company also highlighted preclinical findings from human brain studies showing BHV-8100 increased cerebral glucose utilization and lactate production by up to three times, suggesting improved brain energy metabolism.The effects were particularly pronounced in brains from patients with Alzheimer's disease, it said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BHV","LU1093756325.SGD","BK4139","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640395626","title":"Biohaven starts first-in-human Phase 1 trial of oral PKM2 modulator BHV-8100","url":"https://stock-news.laohu8.com/highlight/detail?id=2640395626","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640395626?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:32","pubTimestamp":1780313579,"startTime":"0","endTime":"0","summary":"Biohaven began first-in-human dosing of BHV-8100, an oral, brain-penetrant PKM2 modulator, in a Phase 1 study in healthy participants.Early results have already been presented from the ongoing trial, showing tolerability consistent with continued dose escalation and a profile supporting once-daily dosing.Separate human brain model work also already reported showed signs of improved brain energy use, with a stronger effect in Alzheimer’s donor tissue.The program positions BHV-8100 as a potential platform asset across neurodegenerative, neuroinflammatory, retinal, and selected systemic inflammatory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL63ZH7f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756325.SGD","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639609290","title":"Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639609290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639609290?lang=en_us&edition=fundamental","pubTime":"2026-05-30 22:30","pubTimestamp":1780151414,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Ltd. (BHVN) and Abivax SA Sponsored ADR (AB...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biohaven-ltd-bhvn-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biohaven-ltd-bhvn-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVX","LU1093756168.USD","LU1093756325.SGD","BK4139","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638692531","title":"Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638692531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638692531?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:20","pubTimestamp":1779981606,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MannKind (MNKD), Biohaven Ltd. (BHVN) and Precisio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-mannkind-mnkd-biohaven-ltd-bhvn-and-precision-biosciences-dtil-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-mannkind-mnkd-biohaven-ltd-bhvn-and-precision-biosciences-dtil-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BHVN","BK4139","LU0029874061.USD","LABU","MNKD","XLV","BK4588","HCSG","BK4581","XBI","BK4584","DTIL","LU1093756325.SGD","LU1093756168.USD","LU0128526141.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638660707","title":"Canaccord Genuity Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638660707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638660707?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:38","pubTimestamp":1779968331,"startTime":"0","endTime":"0","summary":"In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biohaven Ltd., with a price target of $21.00. Accordi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667108","title":"Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667108","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638667108?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:01","pubTimestamp":1779966088,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN). Phreesia...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phreesia-phr-mckesson-mck-and-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phreesia-phr-mckesson-mck-and-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1506573853.SGD","LU1023059063.AUD","LU1934455277.USD","PHR","LU2112291526.USD","LU1934455194.USD","LU0965508806.USD","LU1061106388.HKD","BK4175","BHVN","LU1983260115.SGD","LU0029874061.USD","BK4167","BK4137","LU0048573561.USD","LU1366192091.USD","MCK","LU0868494708.USD","LU1037948897.HKD","LU0861579265.USD","LU0942090050.USD","LU1934455863.HKD","LU1037948541.HKD","LU1057294990.SGD","LU0965509101.SGD","LU1093756325.SGD","LU2324357040.USD","LU1814569148.SGD","BK4139","LU0203347892.USD","BK4533","LU0128526141.USD","HCSG","BK4588","LU0251142724.SGD","BK4581","LU0742534661.SGD","LU1093756168.USD","LU0203345920.USD","LU0314106906.USD","LU0965509283.SGD","LU0122379950.USD","XLV","LU2089984988.USD","LU0251131958.USD","XBI","LU0124676726.USD","LU0868494617.USD","LABU","LU0689626769.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638021845","title":"Biohaven says BHV-1300 cuts Graves’ disease autoantibodies by over 80% in Phase 1b study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638021845","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638021845?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:32","pubTimestamp":1779881533,"startTime":"0","endTime":"0","summary":"Biohaven disclosed new Phase 1b patient data, presented at its R&D and Analyst Day, for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy.BHV-1300 showed rapid, sustained lowering of disease-driving antibodies, with thyroid hormone normalization in treated Graves’ patients.BHV-1400 produced fast, selective reductions in the pathogenic antibody linked to IgA nephropathy, with early signals of improved kidney measures.Both programs showed a tolerable safety profile, with no serious events reported in the patient studies.Pivotal Phase 3 trials for both assets are slated to start in the coming weeks by mid-2026, using a self-administered autoinjector.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL78StS0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU1093756325.SGD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638750295","title":"Biohaven Reports Positive Clinical Biomarker and Patient Data: First Mode and Trap Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2638750295","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638750295?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:30","pubTimestamp":1779881401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA49PWZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","BHVN","BK4139","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638524503","title":"Biohaven (BHVN) Is Up 20.0% After Promising Opakalim Epilepsy Data Release Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2638524503","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638524503?lang=en_us&edition=fundamental","pubTime":"2026-05-27 08:36","pubTimestamp":1779842198,"startTime":"0","endTime":"0","summary":"Biohaven has released new clinical data on its Kv7.2/7.3 activator opakalim, showing longer time to second generalized tonic-clonic seizure in idiopathic generalized epilepsy, meaningful seizure reductions in refractory focal epilepsy, and encouraging results in a compassionate-use KCNQ2-DEE case, all with a low rate of central nervous system side effects.\nA distinctive aspect of the update is opakalim’s once-daily dosing without titration and its cleaner tolerability profile versus other...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-is-up-200-after-promising-opakalim-epilepsy-da","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-is-up-200-after-promising-opakalim-epilepsy-da","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638529111","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638529111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638529111?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:50","pubTimestamp":1779839409,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX). Biohaven Ltd. (B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-biohaven-ltd-bhvn-and-immix-biopharma-immx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-biohaven-ltd-bhvn-and-immix-biopharma-immx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","LU1093756168.USD","BK4139","BK4588","HCSG","LU0128526141.USD","LU1093756325.SGD","LU0029874061.USD","LABU","BK4581","IMMX","BHVN","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638491485","title":"Biohaven Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2638491485","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638491485?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:44","pubTimestamp":1779813840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 12:44 ET (16:44 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","LU1093756325.SGD","LU1093756168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638954994","title":"Biohaven Gains After New Data From Epilepsy-Treatment Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2638954994","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638954994?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:39","pubTimestamp":1779813540,"startTime":"0","endTime":"0","summary":"Shares of Biohaven advanced after the biopharmaceutical company reported new data from studies of its treatment for focal epilepsy.The stock rose 7.4%, to $10.15, midday Tuesday, but are still down 10% year to date.The company's studies involve Opakalim, a drug that acts as a selective activator of Kv7.2/7.3 potassium channels in the brain to prevent seizures. The drug is currently in Phase 2/3 studies for the treatment of focal epilepsy.The company said a randomized, double-blind clinical trial showed that subjects who took opakalim had a longer time before experiencing a second day with a generalized tonic-clonic seizure, compared with the placebo group.The company also said a continuing open-label extension study in focal epilepsy showed 54% of patients with focal epilepsy on opakalim showed a more than 50% reduction in seizure frequency over six months of treatment compared with the baseline.Biohaven said it is on track to announce the top-line results from first of the two Phase 2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biohaven Gains After New Data From Epilepsy-Treatment Studies","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756325.SGD","LU1093756168.USD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638517872","title":"Biohaven reports data from selective Kv7.2/7.3 channel activator program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638517872","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638517872?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:55","pubTimestamp":1779800110,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) reported new data from its selective Kv7.2/7.3 channel activator program, currently in Phase 2/3 studies for the treatment of focal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-reports-data-from-selective-kv7-2-7-3-channel-activator-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-reports-data-from-selective-kv7-2-7-3-channel-activator-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1093756325.SGD","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519273","title":"Biohaven says opakalim triples median time to second seizure day in idiopathic generalized epilepsy trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519273","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519273?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:31","pubTimestamp":1779795101,"startTime":"0","endTime":"0","summary":"Biohaven flagged new clinical data for epilepsy drug opakalim, with additional updates set for presentation at its R&D Day on May 27, 2026.A small controlled study in idiopathic generalized epilepsy showed a clear signal of improved seizure control versus placebo.An ongoing open-label study in refractory focal epilepsy showed many patients sustained meaningful reductions in seizure frequency over extended treatment.A compassionate-use case in a child with KCNQ2-related epilepsy indicated continued clinical stability with ongoing seizure control.Biohaven reiterated plans for top-line results in 2H 2026 from the first of two pivotal Phase 2/3 studies in refractory focal epilepsy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL6jrc4W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4139","LU1093756325.SGD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519255","title":"Biohaven Ltd - on Track for Top-Line Phase 2/3 Results in Refractory Focal Epilepsy in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519255?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:31","pubTimestamp":1779795064,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230I6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1093756325.SGD","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519253","title":"Biohaven Reports New Clinical Data in Epilepsy With Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519253?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:31","pubTimestamp":1779795064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230I6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1093756325.SGD","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638192935","title":"Biohaven Ltd - Opakalim Prolongs Median Time to Second Seizure to 141 Days VS. 47 Days for Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2638192935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638192935?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:31","pubTimestamp":1779795064,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230I6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","BK4139","BHVN","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637316206","title":"Bank of America Securities Reaffirms Their Hold Rating on Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637316206","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637316206?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:18","pubTimestamp":1779448718,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Dina Ramadane maintained a Hold rating on Biohaven Ltd. today and set a price target of $12.00. According to Tip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-hold-rating-on-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-hold-rating-on-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAC","BHVN","PGF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biohaven.com","stockEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":0.0757},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.1309},{"period":"1year","weight":-0.3333},{"period":"ytd","weight":-0.0434}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.071849},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.026101},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.120539},{"month":4,"riseRate":0.555556,"avgChangeRate":0.027819},{"month":5,"riseRate":0.666667,"avgChangeRate":0.144578},{"month":6,"riseRate":0.5,"avgChangeRate":0.048499},{"month":7,"riseRate":0.555556,"avgChangeRate":0.010799},{"month":8,"riseRate":0.666667,"avgChangeRate":0.043364},{"month":9,"riseRate":0.777778,"avgChangeRate":0.09598},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.072057},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.042561},{"month":12,"riseRate":0.555556,"avgChangeRate":0.054983}],"exchange":"NYSE","name":"Biohaven Pharmaceutical Holding Co Ltd.","nameEN":"Biohaven Pharmaceutical Holding Co Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biohaven Pharmaceutical Holding Co Ltd.,BHVN,Biohaven Pharmaceutical Holding Co Ltd.股票,Biohaven Pharmaceutical Holding Co Ltd.股票老虎,Biohaven Pharmaceutical Holding Co Ltd.股票老虎国际,Biohaven Pharmaceutical Holding Co Ltd.行情,Biohaven Pharmaceutical Holding Co Ltd.股票行情,Biohaven Pharmaceutical Holding Co Ltd.股价,Biohaven Pharmaceutical Holding Co Ltd.股市,Biohaven Pharmaceutical Holding Co Ltd.股票价格,Biohaven Pharmaceutical Holding Co Ltd.股票交易,Biohaven Pharmaceutical Holding Co Ltd.股票购买,Biohaven Pharmaceutical Holding Co Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}